Role of the histamine system in nefopam-induced antinociception in mice

被引:20
作者
Girard, P [1 ]
Pansart, Y [1 ]
Coppé, MC [1 ]
Verniers, D [1 ]
Gillardin, JM [1 ]
机构
[1] Lab Biocodex, Serv Pharmacol, F-60200 Compiegne, France
关键词
nefopam; histamine; nociception; writhing; formalin;
D O I
10.1016/j.ejphar.2004.09.030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study explored the role of the histaminergic system in nefopam analgesia based on the structural relationship between nefopam and diphenhydramine. In vitro binding assays revealed that nefopam possesses moderate affinity for histamine H-1 and H-2 receptor subtypes, with IC50 of 0.8 and 6.9 muM, respectively, but no affinity for histamine H-3 receptor subtype until 100 muM. Subcutaneous nefopam administration dose-dependently inhibited pain in acetic acid-induced writhing (1-30 mg/kg) and formalin (1-10 mg/kg) tests in the mouse. Pretreatment with the histamine-depleting agent alpha-fluoromethylhistidine (alpha-FMH, 50 mg/kg), the histamine H, receptor antagonist pyrilamine (3 or 10 mg/kg), or the histamine H-2 receptor antagonists cimetidine (100 mg/kg) and zolantidine (10 or 30 mg/kg) did not significantly modify nefopam antinociception in both tests. The histamine H-3 receptor agonist R(-)alpha-methylhistamine (RAMH, 10 mg/kg) did not significantly modify the nefopam analgesic activity in the writhing test. At 25 mg/kg, RAMH inhibited nefopam antinociception at 3 mg/kg, but not at 10 mg/kg in the formalin test. However, pretreatment with the histamine H-3 receptor antagonist thioperamide (25 mg/kg) inhibited nefopam antinociception in the writhing test, but not in the formalin test. In conclusion, nefopam analgesic activity is not mediated by histamine H-1 or H-2 receptors, but can be slightly modulated by histamine H-3 receptors in mouse pain tests. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 47 条
[1]   Pharmacology of cizolirtine:: A new analgesic agent [J].
Alvarez, I ;
Andreu, F ;
Buxens, J ;
Colombo, M ;
Dordal, A ;
Fort, M ;
Gutiérrez, B ;
Farré, AJ .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2000, 22 (04) :211-221
[2]   HIGHLY POTENT AND SELECTIVE LIGANDS FOR HISTAMINE RECEPTORS-H-3 [J].
ARRANG, JM ;
GARBARG, M ;
LANCELOT, JC ;
LECOMTE, JM ;
POLLARD, H ;
ROBBA, M ;
SCHUNACK, W ;
SCHWARTZ, JC .
NATURE, 1987, 327 (6118) :117-123
[3]  
ARRANG JM, 1994, CELL MOL BIOL, V40, P275
[4]   COMPARISON OF ANALGESIC EFFECT OF INTRAMUSCULAR NEFOPAM AND MORPHINE IN PATIENTS WITH POSTOPERATIVE PAIN [J].
BEAVER, WT ;
FEISE, GA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 17 (10) :579-591
[5]   PHARMACOLOGICAL STUDIES WITH SK AND F-93944 (TEMELASTINE), A NOVEL HISTAMINE H-1-RECEPTOR ANTAGONIST WITH NEGLIGIBLE ABILITY TO PENETRATE THE CENTRAL-NERVOUS-SYSTEM [J].
BROWN, EA ;
GRIFFITHS, R ;
HARVEY, CA ;
OWEN, DAA .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (03) :569-578
[6]   The physiology of brain histamine [J].
Brown, RE ;
Stevens, DR ;
Haas, HL .
PROGRESS IN NEUROBIOLOGY, 2001, 63 (06) :637-672
[7]   Effects of nefopam on the spinal nociceptive processes: a c-Fos protein study in the rat [J].
Buritova, J ;
Besson, JM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 441 (1-2) :67-74
[8]   ZOLANTIDINE (SK-AND-F-95282) IS A POTENT SELECTIVE BRAIN-PENETRATING HISTAMINE H-2-RECEPTOR ANTAGONIST [J].
CALCUTT, CR ;
GANELLIN, CR ;
GRIFFITHS, R ;
LEIGH, BK ;
MAGUIRE, JP ;
MITCHELL, RC ;
MYLEK, ME ;
PARSONS, ME ;
SMITH, IR ;
YOUNG, RC .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 93 (01) :69-78
[9]   HISTAMINE H-3 RECEPTORS MODULATE THE RELEASE OF [H-3] ACETYLCHOLINE FROM SLICES OF RAT ENTORHINAL CORTEX - EVIDENCE FOR THE POSSIBLE EXISTENCE OF H-3 RECEPTOR SUBTYPES [J].
CLAPHAM, J ;
KILPATRICK, GJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (04) :919-923
[10]  
CONWAY AC, 1977, ARCH INT PHARMACOD T, V226, P156